Biomarkers Of Mild Cognitive Impairment And Alzheimer's Disease


A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.

Download PDF
Document Preview
Document History
  • Publication: Dec 14, 2010
  • Application: Jul 25, 2006
    US US 45976306 A
  • Priority: Jul 25, 2006
    US US 45976306 A

Download Citation

Sign in to the Lens